Medicines for Europe Director General Adrian van de Hoven participated in the Open Public Hearing (OPH) of the July 13, 2017 Oncologic Drugs Advisory Committee US FDA Advisory Committee involving biosimilar medicines on 13 July 2017.

• Biosimilar medicines clinical use: an experience based-EU perspective
• The Biosimilar Medicines Group contribution to the US FDA Docket
• For more information please check the official US FDA website